1-4 of 4
Kevin W. H. Yee
Close
Sort by
Journal Articles

Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD–positive leukemic cells

Kevin W. H. Yee, Marcus Schittenhelm, Anne-Marie O'Farrell, Ajia R. Town, Laura McGreevey, Troy Bainbridge, Julie M. Cherrington, Michael C. Heinrich
Journal: Blood
Blood (2004) 104 (13): 4202–4209.
https://doi.org/10.1182/blood-2003-10-3381
Published: 2004
Journal Articles

Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970

Brief Report
Amie S. Corbin, Ian J. Griswold, Paul La Rosée, Kevin W. H. Yee, Michael C. Heinrich, Corinne L. Reimer, Brian J. Druker, Michael W. N. Deininger
Journal: Blood
Blood (2004) 104 (12): 3754–3757.
https://doi.org/10.1182/blood-2004-06-2189
Published: 2004
Journal Articles

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

Anne-Marie O'Farrell, Tinya J. Abrams, Helene A. Yuen, Theresa J. Ngai, Sharianne G. Louie, Kevin W. H. Yee, Lily M. Wong, Weiru Hong, Leslie B. Lee, Ajia Town, Beverly D. Smolich, William C. Manning, Lesley J. Murray, Michael C. Heinrich, Julie M. Cherrington
Journal: Blood
Blood (2003) 101 (9): 3597–3605.
https://doi.org/10.1182/blood-2002-07-2307
Published: 2003
Journal Articles

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

Kevin W. H. Yee, Anne Marie O'Farrell, Beverly D. Smolich, Julie M. Cherrington, Gerald McMahon, Cecily L. Wait, Laura S. McGreevey, Diana J. Griffith, Michael C. Heinrich
Journal: Blood
Blood (2002) 100 (8): 2941–2949.
https://doi.org/10.1182/blood-2002-02-0531
Published: 2002